Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GSK PLC Sponsored ADR stock logo
GSK
GSK
$53.16
+3.9%
$53.26
$35.45
$61.69
$107.76B0.364.84 million shs3.85 million shs
Nuvalent, Inc. stock logo
NUVL
Nuvalent
$123.41
+0.0%
$103.44
$71.13
$123.62
$9.76B1.151.17 million shs5.63 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.33
+2.8%
$26.52
$23.11
$28.75
$150.21B0.3440.92 million shs31.21 million shs
Roche Holding AG stock logo
RHHVF
Roche
$419.72
+4.4%
$405.15
$300.15
$490.33
N/AN/A17,496 shs988 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GSK PLC Sponsored ADR stock logo
GSK
GSK
+0.12%+2.97%+2.81%-5.67%+24.02%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
+0.08%+36.78%+17.98%+25.87%+55.24%
Pfizer Inc. stock logo
PFE
Pfizer
-0.24%+0.95%-0.83%-4.62%+5.39%
Roche Holding AG stock logo
RHHVF
Roche
+0.81%+3.47%-2.09%-6.46%+22.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GSK PLC Sponsored ADR stock logo
GSK
GSK
$53.16
+3.9%
$53.26
$35.45
$61.69
$107.76B0.364.84 million shs3.85 million shs
Nuvalent, Inc. stock logo
NUVL
Nuvalent
$123.41
+0.0%
$103.44
$71.13
$123.62
$9.76B1.151.17 million shs5.63 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.33
+2.8%
$26.52
$23.11
$28.75
$150.21B0.3440.92 million shs31.21 million shs
Roche Holding AG stock logo
RHHVF
Roche
$419.72
+4.4%
$405.15
$300.15
$490.33
N/AN/A17,496 shs988 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GSK PLC Sponsored ADR stock logo
GSK
GSK
+0.12%+2.97%+2.81%-5.67%+24.02%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
+0.08%+36.78%+17.98%+25.87%+55.24%
Pfizer Inc. stock logo
PFE
Pfizer
-0.24%+0.95%-0.83%-4.62%+5.39%
Roche Holding AG stock logo
RHHVF
Roche
+0.81%+3.47%-2.09%-6.46%+22.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.00
Hold$53.001.06% Upside
Nuvalent, Inc. stock logo
NUVL
Nuvalent
2.20
Hold$131.156.28% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.25
Hold$28.8210.16% Upside
Roche Holding AG stock logo
RHHVF
Roche
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NUVL, GSK, PFE, and RHHVF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/10/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Reiterated RatingOutperform
6/10/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
DowngradeBuyNeutral$151.00 ➝ $124.00
6/10/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
DowngradeBuyNeutral$138.00 ➝ $124.00
6/10/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
DowngradeBuyNeutral$138.00 ➝ $124.00
6/9/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeUnderperformSector Perform$25.00
6/9/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Set Price Target$124.00
6/9/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
DowngradeBuyHold$124.00
6/9/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Reiterated RatingOverweightEqual Weight$152.00 ➝ $124.00
6/9/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Reiterated RatingOutperform
6/9/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Set Price Target$122.85
6/9/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Set Price Target$124.00
(Data available from 6/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GSK PLC Sponsored ADR stock logo
GSK
GSK
$32.78B3.25$6.15 per share8.53$10.32 per share5.08
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/A$15.95 per shareN/A
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.38$4.47 per share5.85$15.26 per share1.71
Roche Holding AG stock logo
RHHVF
Roche
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GSK PLC Sponsored ADR stock logo
GSK
GSK
$7.54B$3.8513.6210.242.6317.82%44.28%11.49%7/28/2026 (Estimated)
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3119.979.15N/A11.83%19.44%8.41%8/4/2026 (Estimated)
Roche Holding AG stock logo
RHHVF
Roche
N/A$10.8138.83N/AN/AN/AN/AN/AN/A

Latest NUVL, GSK, PFE, and RHHVF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.813.45%-7.86%47.01%N/A
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.57%-13.20%131.30%16 Years
Roche Holding AG stock logo
RHHVF
Roche
$7.801.86%N/A72.16%N/A

Latest NUVL, GSK, PFE, and RHHVF Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.443.71%5/15/20265/15/20267/9/2026
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.71%5/8/20265/8/20266/12/2026
1/1/2100
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42064.3%8/15/20258/15/202510/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.80
0.79
0.52
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/A
16.14
16.14
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.25
0.94
Roche Holding AG stock logo
RHHVF
Roche
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
97.26%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Roche Holding AG stock logo
RHHVF
Roche
29.01%

Insider Ownership

CompanyInsider Ownership
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
5.02%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
Roche Holding AG stock logo
RHHVF
Roche
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
66,8412.03 billion1.83 billionOptionable
Nuvalent, Inc. stock logo
NUVL
Nuvalent
4079.00 million75.03 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable
Roche Holding AG stock logo
RHHVF
Roche
103,605N/AN/ANot Optionable

Recent News About These Companies

Roche (OTCMKTS:RHHVF) Stock Price Down 4.2% - Time to Sell?
Roche Q1 sales down on forex effects

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
GSK stock logo

GSK NYSE:GSK

$53.16 +1.99 (+3.89%)
As of 03:42 PM Eastern
This is a fair market value price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Nuvalent stock logo

Nuvalent NASDAQ:NUVL

$123.41 +0.06 (+0.05%)
As of 03:42 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Pfizer stock logo

Pfizer NYSE:PFE

$26.33 +0.73 (+2.84%)
As of 03:42 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Roche stock logo

Roche OTCMKTS:RHHVF

$419.72 +17.50 (+4.35%)
As of 03:15 PM Eastern

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.